Table 1.

Feasibility and hurdles to indication-based pricing

Country	Legal feasibility	Data collection feasibility	Billing feasibility	Other hurdles
Germany	Not within the current German Social Code book	Limited	Limited	Lack of incentives
France	Yes	Restricted (expensive drugs provided by hospitals)	Restricted (expensive drugs provided by hospitals)	Lack of incentives; physician resistance
Italy	Not with current price-setting by AIFA	Yes, full with registries	Yes, full with registries	Physician resistance; extra cost for registries
Spain	Yes	Yes	Yes	IT limitations; regional fragmentation; indication appropriateness
England	Yes	Yes	Yes	Budget fragmentation
Sweden	Yes	Limited	Hospital	Indication shift